Clinical trials: Oligometastatic Prostate Carcinoma
Oligometastatic Hormone Sensitive Prostate Cancer
Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients
INDICATION: Oligometastatic hormone-sensitive prostate cancer patients. METHODOLOGY: Open label, double arm, randomized 1:1, multicenter phase III study.
- Trial name
- Oligo-PRESTO (NCT04115007)
- Testing
- Stereotactic Body Radiotherapy (SBRT) + Standard of care, Standard of care
- Where
- 35 sites in France, Martinique
- Volunteers
- 550 people
- Sponsor
- UNICANCER
PROSTATE CANCER
Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer
The main purpose of this study is to find out whether adding radiation therapy to the standard treatment of chemotherapy for prostate cancer is tolerated well and is more effective than the standard treatment of chemotherapy alone
- Trial name
- NCT01087580
- Testing
- Docetaxel and Prednisone, Radiation Therapy
- Where
- 2 sites in United States
- Sponsor
- Northwestern University
Prostate Cancer, Oligometastases
Stereotactic Body Radiation for Prostate Oligometastases
Men with oligometastatic prostate cancer lesions will be randomized (1:2) to observation versus SBRT. The study will NOT be blinded. Within three weeks of the initial treatment planning, SBRT (1-5 fractions) will be administered.
- Trial name
- ORIOLE (NCT02680587)
- Testing
- SBRT
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer, Metastatic Prostate Cancer
Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer
This is an ambispective, multicenter, observational real-world registry of patients with synchronous de novo oligometastatic prostate cancer, defined as prostate cancer with up to 10 extraregional metastatic lesions diagnosed at…
- Conditions
- Prostate Cancer, Metastatic Prostate Cancer, Oligometastatic Prostate Cancer, Synchronous Oligometastatic Prostate Cancer
- Trial name
- SynSABR-PC (NCT07686016)
- Testing
- Definitive Prostate-Directed Radiotherapy, Metastasis-Directed Stereotactic Body Radiotherapy, Pelvic Lymph Node Irradiation
- Where
- Poland
- Volunteers
- 700 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Prostate Cancer
PSMA-PET Guided Radiotherapy
PSMA PET/CT has demonstrated higher sensitivity in detecting metastases than current imaging standard of care (CT and bone scan). [18F]DCFPyL is a promising high-sensitivity second generation PSMA-targeted urea-based PET probe.
- Trial name
- PSMA-PETgRT (NCT03525288)
- Testing
- PSMA -PET/CT simulation, Standard-care simulation
- Where
- 3 sites in Canada
- Volunteers
- 130 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Prostatic Neoplasms
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
This is a non-comparative open-label multicenter Phase 2 clinical trial combining stereotactic body radiation therapy (SBRT) and pembrolizumab with or without intratumoral SD-101 in participants with newly diagnosed hormone-naive…
- Trial name
- NCT03007732
- Testing
- Pembrolizumab, SD-101, Leuprolide acetate
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- David Oh
Prostate Cancer (Adenocarcinoma), OligoProgressive Metastatic Disease
The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)
In patients with metastatic prostate cancer (PCa) who receive androgen deprivation therapy (ADT), the sensitivity to castration will eventually disappear due to the selection of castration-refractory clones.
- Conditions
- Prostate Cancer (Adenocarcinoma), OligoProgressive Metastatic Disease, Castration Resistant Metastatic Prostate Cancer, Radiotherapy
- Trial name
- OLYMPIAN (NCT07038304)
- Testing
- Metastasis directed radiotherapy
- Where
- 2 sites in Netherlands
- Volunteers
- 35 people
- Sponsor
- University Medical Center Groningen
Prostate Cancer
Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer
This study is evaluating whether adding stereotactic radiotherapy (a new, more focused type of radiotherapy) to treat all the tumours that are present will improve outcomes or not compared to drugs alone for patients who are…
- Trial name
- NCT04619069
- Testing
- SBRT, Hormone therapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Sunnybrook Health Sciences Centre
Breast Cancer, Prostate Cancer
OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)
The goal of this clinical trial is to evaluate single-fraction metastases-directed SBRT in the broader radiation oncology community and to compare its safety and efficacy profile with the current Standard of Care (SoC) of…
- Conditions
- Breast Cancer, Prostate Cancer, NSCLC, Colorectal Cancer
- Trial name
- SPRINT (NCT06462963)
- Testing
- single-fraction SBRT, multiple-fraction SBRT
- Where
- 15 sites in Belgium, Italy and 2 more
- Volunteers
- 302 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma
177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
This phase II trial tests whether 177-Lutetium-PSMA given before stereotactic body radiotherapy (SBRT) works to improve cancer control rate in patients with 1-5 prostate cancer tumors that have come back after prior treatment…
- Conditions
- Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- LUNAR (NCT05496959)
- Testing
- Lutetium Lu-177 PNT2002, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone
Phase II Randomized Trial of Radiation Therapy in Oligometastatic mCRPC Prostate Cancer (ARTO)
Metastatic castration resistant prostate cancer causes approximately 258400 deaths annually worldwide. In the presence of metastatic disease, systemic treatment remains the main clinical option.
- Trial name
- ARTO (NCT03449719)
- Testing
- SBRT - Ablative radiation Therapy, Abiraterone Acetate
- Volunteers
- 174 people
- Sponsor
- Lorenzo Livi
Oligometastatic Prostate Cancer
Maximal Tumor Eradication for Oligometastatic Prostate Cancer
In China, the incidence of prostate cancer is increasing in recent years, and it has ranked 5th among common male tumors and 1st in urinary tumors.
- Trial name
- NCT06972511
- Testing
- neoadjuvant apatamide plus ADT + radical resection of prostate cancer + extended lymph node dissection + radiotherapy of metastases, Standard ADT treatment
- Where
- China
- Volunteers
- 120 people
- Sponsor
- RenJi Hospital
Prostate Cancer Metastatic, Prostate Cancer Metastatic to Bone
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
PSMA-PET/CT or PSMA-PET/MRI are more accurate imaging modalities compared to CT/BS; in approximately 10-20% of high-risk patients diagnosed using conventional imaging PSMA-PET up-stages the disease.
- Conditions
- Prostate Cancer Metastatic, Prostate Cancer Metastatic to Bone, Prostate Cancer, Prostate Neoplasm
- Trial name
- OLIGOMET (NCT06430411)
- Testing
- Radical prostatectomy, Prostate irradiation, Surgical metastasectomy
- Volunteers
- 500 people
- Sponsor
- Medical University of Vienna
Prostate Cancer Metastatic
Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer
The purpose of this study is to compare the effects of ablative therapy (radiation or surgery) to all sites of disease combined with standard treatments on prostate cancer, compared to the standard or usual treatments used to…
- Trial name
- PLATON (NCT03784755)
- Testing
- Ablative Radiation Therapy, Standard of care
- Where
- 18 sites in Canada
- Volunteers
- 409 people
- Sponsor
- Canadian Cancer Trials Group
Metastatic Castration Resistant Prostate Cancer, Oligometastatic Prostate Cancer (OMPC)
JUR-003 in Adult Patients With Metastatic Prostate Cancer
JUR-003-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of JUR-003 in patients with prostate cancer.
- Conditions
- Metastatic Castration Resistant Prostate Cancer, Oligometastatic Prostate Cancer (OMPC), Metastatic Hormone Sensitive Prostate Cancer
- Trial name
- NCT07824349
- Testing
- JUR-003
- Where
- 4 sites in United States
- Volunteers
- 210 people
- Sponsor
- Juri Biosciences, Inc.
Oligometastatic Prostate Cancer
Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis
A randomized phase II clinical trial (RADIOSA trial: Radioablation with or without Androgen DeprIvation therapy in metachronous prostate cancer OligometaStAsis).
- Trial name
- RADIOSA (NCT03940235)
- Testing
- Androgen deprivation therapy (ADT), SBRT
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- European Institute of Oncology
Stage III Prostate Cancer, Stage IIIA Prostate Cancer
Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer
This phase I trial studies the side effects of anti-PD-1 monoclonal antibody REGN2810 (REGN2810) and/or ipilimumab when given together with stereotactic body radiation therapy before surgery in treating participants with prostate…
- Conditions
- Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer
- Trial name
- NCT03477864
- Testing
- Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), Radical Prostatectomy
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Prostate Cancer
Diagnostic and Prognostic Accuracy of FDHT-PET and Liquid Biopsies in Prostate Cancer
Depending on the cohort of the study the diagnostic and prognostic accuracy and health economics considerations of [18F]-fluoro-5α-dihydrotestosterone (FDHT)- positron emission tomography (PET) and/or circulating tumor cells in…
- Trial name
- NCT05245435
- Testing
- FDHT-PET Scan, liquid biopsies
- Where
- Austria
- Sponsor
- Medical University of Vienna
High Risk Prostate Cancer
Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy and Staged as Oligometastatic With PSMA-PET
This is a phase 2, open-label, randomized study of adjuvant treatment in subjects with high-risk prostate cancer who are candidates for RP with PLND based on M0 status at conventional imaging, but staged as oligometastatic with…
- Trial name
- STAPLE (NCT06758882)
- Testing
- Apalutamide, Androgen receptor (AR) inhibitor
- Where
- Italy
- Volunteers
- 94 people
- Sponsor
- Marco Oderda
Prostate Cancer, Oligometastasis
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate…
- Conditions
- Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer
- Trial name
- VA STARPORT (NCT04787744)
- Testing
- PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease
- Where
- 20 sites in United States
- Volunteers
- 378 people
- Sponsor
- VA Office of Research and Development